Centrally active nonhormonal hot flash therapies

Loprinzi, Charles L.; Stearns, Vered; Barton, Debra L.

doi:10.1016/j.amjmed.2005.09.045

Cited by 35 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, hot flashes occurring during sleep are not accurately reported because recall of these events is often poor and most hot flashes do not produce full awakenings [15]. Finally, placebo effects as large as 40–50% occur with self-report [16]. These factors make self-report a problematic measure of therapeutic efficacy.…”

Section: Discussionmentioning

confidence: 99%

Treatment of menopausal hot flashes with 5-hydroxytryptophan

Freedman¹

2010

Maturitas

View full text Add to dashboard Cite

Objective-Much recent research has focused on nonhormonal treatments for menopausal hot flashes. The purpose of the present study was to determine the effects of 5-Hydroxytroptophan (5-HTP), the immediate precursor of serotonin, upon menopausal hot flashes. Selective, serotonergic, reuptake inhibitors (SSRI's), which increase the amount of serotonin in the synaptic gap, have shown some promise in the amelioration of hot flashes.Methods-We administered 5-HTP or placebo, in double-blind fashion, to 24 postmenopausal women reporting frequent hot flashes. Treatment outcome was measured using a miniature, electronic, hot flash recorder.Results-No significant effects of 150 mg/day 5-HTP upon hot flash frequency were found. The 5-HTP group had 23.8 ± 5.7 (SD) hot flashes/24 hours prior to treatment and 18.5 ± 9.6 at the end of treatment. The placebo group had 18.5 ± 9.6 before treatment and 22.6 ± 12.4 at treatment completion.Conclusions-At the dose given, 5-HTP does not significantly ameliorate frequency of menopausal hot flashes, as measured objectively with an electronic recorder. Given the small size, this study must be considered preliminary in nature.

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment of menopausal hot flashes with 5-hydroxytryptophan

Freedman¹

2010

Maturitas

View full text Add to dashboard Cite

show abstract

“…Since 2000, several selective serotonin reuptake inhibitor (SSRI) and serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants have been studied and been found to decrease hot flash scores by 50–65% 10–12 . However, there are some limitations regarding the use of antidepressants for hot flashes.…”

Section: Introductionmentioning

confidence: 99%

A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes

Pruthi

Qin

Terstreip³

et al. 2012

Menopause

Self Cite

View full text Add to dashboard Cite

Objective Preliminary data suggest that flaxseed, a rich source of dietary lignans, may be a potentially effective treatment for hot flashes. A phase III randomized, placebo controlled trial was conducted to evaluate the efficacy of flaxseed in reducing hot flashes. Methods Postmenopausal women with or without breast cancer were randomly assigned to a flaxseed bar (providing 410 mg of lignans) for 6 weeks vs. a placebo bar. Participants completed daily, prospective, hot flash diaries during the baseline week, and then ate one study bar/day for 6 weeks while recording their daily hot flashes. The intra-patient difference in hot flash activity between baseline and the last treatment week was the primary endpoint. Side effects were evaluated through self report and CTC assessment. Results 188 women were enrolled onto this trial. Mean hot flash score was reduced 4.9 in the flaxseed group and 3.5 in the placebo group (p=.29). In both groups, a little over a third of the women received a 50% reduction in their hot flash score. Only one side effect was significantly different between groups, grade 1 pruritis, which was more common in the placebo group (8% versus 1%). Both groups reported abdominal distension, flatulence, diarrhea and nausea. Adherence and ability to detect treatment assignment did not differ between groups. Conclusions The results of this trial do not support the use of 410 mg of lignans for the reduction of hot flashes. The bars were fairly well tolerated, with both groups reporting gastrointestinal effects, likely due to the fiber content.

show abstract

“…B. bei Patientinnen mit Mammakarzinom) treten häufig Nebenwirkungen auf, die als " hot flashes" bezeichnet werden. Diese Nebenwirkungen können mit selectiven serotonin reuptake inhibitors (SSRIs) aber auch mit Mirtazapin und Venlafaxin erfolgreich behandelt werden, wobei gleichzeitig positive Effekte auf die Stimmungsstabilität der Patientinnen berichtet werden (Loprinzi et al 2000;Stearns u. Loprinzi 2003;Loprinzi et al 2006;Loprinzi et al 2005). …”

Section: Behandlung Von "Hot Flashes"unclassified

Psychopharmakatherapie bei Patienten mit onkologischen Erkrankungen

Sperner‐Unterweger

2007

Psychiatrie

View full text Add to dashboard Cite

Centrally active nonhormonal hot flash therapies

Cited by 35 publications

References 33 publications

Treatment of menopausal hot flashes with 5-hydroxytryptophan

Treatment of menopausal hot flashes with 5-hydroxytryptophan

A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes

Psychopharmakatherapie bei Patienten mit onkologischen Erkrankungen

Contact Info

Product

Resources

About